Allogene Therapeutics initiated with an Outperform at Raymond James Raymond James analyst Dane initiated Allogene Therapeutics with an Outperform rating and a price target of $40. The analyst says the analysis of the company’s CAR T cell therapies in UCART19 CALM and PALL study suggests a “competitive profile vs. autologous CD19+ CAR T cell products and supports a positive outlook for ALLO-501”. Leone adds that while there are “questions surrounding the correlation of persistence and durable outcomes from the studies”, he believes that the “potential to re-dose ALLO-501 balances this risk”.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.